Clinical Trial

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Name: Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease — clinical trial record (NCT04838301)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: REGEN-BRAIN©

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

Protocol Amendment History 1 change

critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-01

Trial Details

NCT Number	NCT04838301
Lead Sponsor	University of Arizona Collaborators: National Institute on Aging (NIA), Syneos Health, University of Southern California, ADM Diagnostics
Conditions	Alzheimer Dementia, Late Onset Alzheimer Disease, Neurodegenerative Diseases
Enrollment	100 participants
Start Date	2023-08-15
Primary Completion	2026-11-18 (estimated)
Study Completion	2027-03-18 (estimated)
Updated on ClinicalTrials.gov	2026-06-30